In the last trading session, 12.63 million Vera Therapeutics Inc (NASDAQ:VERA) shares changed hands as the company’s beta touched 1.11. With the company’s per share price at $22.70 changed hands at -$7.93 or -25.89% during last session, the market valuation stood at $1.45B. VERA’s last price was a discount, traded about -127.36% off its 52-week high of $51.61. The share price had its 52-week low at $18.53, which suggests the last value was 18.37% up since then.
Analysts gave the Vera Therapeutics Inc (VERA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 1 recommended VERA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Vera Therapeutics Inc’s EPS for the current quarter is expected to be -0.63.
Vera Therapeutics Inc (NASDAQ:VERA) trade information
Instantly VERA was in red as seen at the end of in last trading. With action 19.79%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -46.32%, with the 5-day performance at 19.79% in the green. However, in the 30-day time frame, Vera Therapeutics Inc (NASDAQ:VERA) is 0.35% up.
The consensus price target for the stock as assigned by Wall Street analysts is 65, meaning bulls need an upside of 65.08% from its current market value. According to analyst projections, VERA’s forecast low is 65 with 65 as the target high. To hit the forecast high, the stock’s price needs a -186.34% plunge from its current level, while the stock would need to soar -186.34% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.49%. The 2025 estimates are for Vera Therapeutics Inc earnings to decrease by -20.32%, but the outlook for the next 5-year period is at 12.94% per year.
VERA Dividends
Vera Therapeutics Inc is expected to release its next quarterly earnings report in July.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.6147% or 3.62 million shares worth $130.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 1.68 shares estimated at $38.09 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.35% of the shares, roughly 1.5 shares worth around $34.08 million.
